Haleon PLC

Board/Management Information • Oct 3, 2024

National Storage Mechanism | Additional information

RNS Number : 8361G

Haleon PLC

03 October 2024

 

Haleon plc: Director Declaration

3 October 2024: In accordance with paragraph 6.4.9R of the Listing Rules, Haleon plc hereby gives notification that Alan Stewart stepped down from the Board of Diageo plc on 26 September 2024.

Amanda Mellor  

Company Secretary  

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit   www.haleon.com . 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNMJBLTMTJMMII